RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential

Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential.

Analyst Commentary

Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises. The latest target raises into the mid $160s bracket are framed as a recalibration to reflect improved confidence in the company s ability to sustain above market growth while navigating macro and funding headwinds.

Recent research notes highlight that the third quarter revenue beat, coupled with broad based growth and particular strength in Process Analytics, supports the view that Repligen is exiting the trough in demand. Analysts see the current setup as a blend of stabilizing end markets, operational leverage, and a still reasonable valuation, especially relative to the company s double digit growth profile in bioprocessing solutions.

At the same time, valuation updates suggest that while near term rating stances may remain balanced, underlying assumptions on revenue trajectories and margin expansion are being nudged higher. This has contributed to a gradual reset of price targets closer to the firm s long term fair value estimates, reinforcing the case for continued upside if execution remains consistent and the recovery in bioprocessing spend accelerates.

Bullish Takeaways

• Price targets have been raised into a $160 to $165 range, reflecting improved confidence in Repligen s medium term growth outlook and narrowing the gap between market targets and intrinsic value estimates.
• Bullish analysts point to the 3Q25 revenue beat and growth across all franchises, led by Process Analytics, as evidence of robust execution and early signs of a more durable recovery in bioprocessing demand.
• Sentiment indicators suggest that investor pessimism may have bottomed, with stabilizing end markets and more attractive share valuations viewed as catalysts for multiple expansion as growth reaccelerates.
• New coverage with a Buy rating and a $150 target underscores the view that Repligen s bioprocessing portfolio and volume leverage in a recovery are underappreciated, supporting expectations for sustained double digit revenue growth.

What's in the News

• Repligen raised its full year 2025 revenue guidance to $729 to $737 million, implying 14% to 15.5% year over year non COVID organic growth, and now expects income from operations of $50 million to $52 million and diluted EPS of $0.82 to $0.85 (company guidance).
• The company reported that, from July 1, 2025 to September 30, 2025, it repurchased no additional shares under the long standing buyback announced on June 18, 2008, but has fully completed that program with a total of 592,827 shares repurchased, representing 1.9% for $2.28 million (company filing).
• Repligen also reported no share repurchases in the same period under the more recent buyback announced on December 7, 2023, but confirmed completion of that authorization as well, with 92,090 shares repurchased in total, representing 0.16% for $14.4 million (company filing).

Valuation Changes

• The fair value estimate was nudged slightly lower from $220.00 to approximately $216.62 per share, reflecting modestly more conservative assumptions.
• The discount rate increased slightly from about 7.39% to roughly 7.89%, implying a marginally higher required return and risk premium.
• Revenue growth was trimmed modestly from around 17.32% to approximately 16.21% long term, signaling slightly lower expectations for top line expansion.
• The net profit margin was raised marginally from about 14.36% to roughly 14.43%, indicating a small improvement in projected profitability.
• The future P/E was reduced slightly from roughly 97.7x to about 95.1x, pointing to a modest recalibration in valuation multiples applied to forward earnings.